ReviewSleep & breathing = Schlaf & Atmung2026
Endophenotypes of OSA that are responsive to pharmacological agents: a narrative review of trazodone and atomoxetine.
Review in Sleep & breathing = Schlaf & Atmung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Precision Pharmacotherapy for Obstructive Sleep Apnea: Matching Targeted Drugs to Patient Endophenotypes.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obstructive sleep apnea (OSA) is a common sleep disorder in adults and is associated with multiple brain, mental, and cardiometabolic adverse health outcomes. Although standard treatments are available for OSA, the world does not have equal access to the best management approaches for OSA, which could be due to limited financial resources or a limited trained workforce. Pharmacological agents, if selected wisely based on the endophenotypes of OSA, may offer an appropriate approach for selective cases of OSA who refuse standard treatments or do not have access to the standard care. This review describes different OSA comorbidities, phenotypes, and endotypes of OSA and the role of trazodone and atomoxetine in the management of them. Finally, we will summarize the endophenotypes responsive to trazodone and atomoxetine and highlight the role of these agents in the management of OSA and its consequences, especially in underserved areas.
Indexed as
Identifiers
41945224What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.